Member Info for Matml74

Sky monkey, There would be an rns every week if that were the case. It is not speculation it is bot generated information based on the last set of published accounts.

There are 6 monthly interims by the end of September that will answer anyone’s questions about cash position of the company which is all the company needs to provide.

This all stems from a poster who came on here yesterday who IMO tried to put doubt into investors minds over the cash position of the company. If they were actually invested in the company they would have realised there was a 6 monthly interim due within weeks.

They are now firmly in my filter bin as that kind of posting is a disgrace and blight on LSE.

Think I will just wait for the interim's due this month and take a considered view then rather than Simply Wall Street bot generated articles.

There will be 6 monthly interim's before the end of the month (to June 21). You seem to be trying to worry people about the companies cash position when we will all find out exactly what that is in the very near future.

Someone trying to create uncertainty about the company cash position when it will be clearly stated by the company within weeks is IMO "an opinion to be wary of!"

Picax, You do realise GAD are the manufacturer of the Avacta test?

So far ODX have received SFA of their £300m contract. Anything Bethell says is trying to distract from the fact he funded the Chinese with £4billion to buy a heap of ****ty tests.

Burleigh, The PFS will be published in H2. No posters know exactly when. It can come at any point in time given we are basically halfway through H2 and SD just last week said the PFS is "well advanced".

LOL. Agreed CW. They forget to pay their bills it seems.

Further to this EUA should come with actual orders of drug and associated upfront cash payments.

Only £30million of the placement in October 2020 was for the clinical trial. There were savings there when the trial size was reduced by approximately a third.

£33 million of the placement on October 2020 was for manufacturing of 100k doses per month. Any EUA will come with pre=orders and cash.

Another £6million to be put towards manufacturing processes and regulatory activities.

....... and £10million to strengthen the balance sheet.

One thing this company does not have is a cash issue.

@Goldfinger I suggest you go and do some further research on polygon. There are multiple instances where they have blocked low ball offers for companies they have stakes in. They will do the same here and they will have a clear understanding of the potential value here which is well north of a £1b MCAP (£5) upon successful P3.

I've sent an email off yesterday Jiffy and I encourage all investors to do so. If GGP wants to be a grown up company as Mr Day is talking about they need to move to a more open and liquid trading system.

Some info on SETS here: https://www.londonstockexchange.com/trade/equity-trading/sets

Yep new CEO needed. Will be voting for his removal at AGM. Very poor effort to sell less than half a million quids worth of PCR testing stock when they had CE mark last June. Will hold as they have some decent products and POC will be paramount in the future but think their tech needs to get into the hands of a bigger player.

Polygon going in big! Love it.

@Jamesp21 " but the fact the SP is so easily manipulated may be playing the part in keeping new investors away and forcing those less patient amongst us to sell up."

This is a very good point. This share should not be traded on SEAQ where mm's have complete control. I have written to the company asking why this share is not moved to SETS where direct acesss to market is possible. I am in shares such as SEE and SNG who trade on SETS that have less liquidity than here so it make no sense GGP with its mcap is still in this outdated system.

I have written to the company asking why the move has not happened. I recommend all shareholders put some pressure on the board for a move to SETS.

The thing some are missing here is GDJX ended up buying 200m+ shares from September last year and this saw the SP rise to the 27p region by December.

II buying will see the next big surge and when that happens PI’s will likely pile in again. Just a matter of time.

PFS - Sometime before end of December.
MRE upgrade - December

Spawn,

There will be an upraised to the MRE in December which will include some of the drilling since March. IN 2022 the FS is due which will likely use the updated MRE and be a more robust document than the PFS.

Incoming news:

- 6 monthly Trading Update (end of June 2021) due before end of September
- Activ 2 update
- P3 last patient dosed
- P3 data readout

I expect the remainder of H2 will be news rich!

It should be given before ICU. If on oxygen now is the time. Try the MAP or contact SNG about the trial.

"Managed Access Program
In September 2020, Synairgen plc signed an agreement with Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, to launch a Managed Access Program for Synairgen’s inhaled interferon beta, SNG001, in the UK and the EU for the treatment of hospitalised COVID-19 patients.

Healthcare professionals in the EU can obtain details about the SNG001 Managed Access Program by calling the customer service team at +44(0)1283 494340 or emailing medicineaccess@clinigengroup.com.

Patients seeking information should contact their physician."

20p? - Not whilst Berenberg are controlling things. Continuing their usual antics to keep the SP as low as possible.

https://avacta.com/wp-content/uploads/2021/09/M19-framework-text.pdf